Total revenue increased by 17% to $16.6 million in fiscal year 2025, up from $14.2 million in 2024. Net loss decreased by 15% to $73.6 million in fiscal year 2025, compared to $86.6 million in 2024. Cash used in operating activities improved slightly to $44.4 million in 2025 from $46.1 million in 2024. Research and development expenses decreased by 13% to $43.9 million in 2025. Selling, general and administrative expenses decreased by 25% to $42.6 million in 2025. Launched the Proteograph ONE assay and SP200 automation instrument in May 2025, improving throughput tenfold to over 1,000 samples per week. Served over 190 customers across more than 20 countries since commercial launch in 2021. PrognomiQ, a related party, accounted for 5% of revenue in 2025, down from 17% in 2024. The company holds $240.6 million in cash, cash equivalents, and investments as of December 31, 2025. Achieved ISO 27001 certification for cybersecurity systems and processes in 2025.